Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Springworks Therapeutics Inc (NQ: SWTX )

43.88 +0.90 (+2.09%)
Streaming Delayed Price Updated: 10:43 AM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Springworks Therapeutics Inc

< Previous 1 2 3 4 Next >
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for SpringWorks Therapeutics: Here's What You Need To Know
Via Benzinga
What's Going On With Rare Diseases-Focused SpringWorks Therapeutics Stock Today?
SpringWorks Therapeutics Inc (NASDAQ: SWTX) released topline results from its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with... 
Via Benzinga
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
The Latest Analyst Ratings for SpringWorks Therapeutics
Via Benzinga
SpringWorks Therapeutics: Q1 Earnings Insights
Via Benzinga
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations for SpringWorks Therapeutics's Future
Via Benzinga
SpringWorks' Investigational Cancer Treatment Is Standard Care, Analyst Unfazed By FDA Update
In March, the FDA issued SpringWorks Therapeutics Inc (NASDAQ: SWTX) with a Form 483 letter due to a failure to ensure that the analysis of an exploratory endpoint in the Phase 3 DeFi trial, which... 
Via Benzinga
Exposures Product Safety
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
FDA Extending PDUFA Date by Three Months to Allow More Time to Complete Their Review; New PDUFA Date Set to November 27, 2023 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Get In Now. 7 Stocks That Are Set to Soar.
While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas. 
Via InvestorPlace
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors
– PDUFA Action Date Set for August 27, 2023 – 
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.